Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CAO Craig Gracey sold 2,083 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $18.00, for a total transaction of $37,494.00. Following the completion of the sale, the chief accounting officer directly owned 7,108 shares in the company, valued at $127,944. This trade represents a 22.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Craig Gracey also recently made the following trade(s):
- On Friday, June 12th, Craig Gracey sold 6,894 shares of Omada Health stock. The stock was sold at an average price of $17.42, for a total transaction of $120,093.48.
Omada Health Price Performance
Shares of NASDAQ:OMDA traded up $0.28 during mid-day trading on Wednesday, reaching $18.58. 706,805 shares of the company were exchanged, compared to its average volume of 1,201,429. Omada Health, Inc. has a 1 year low of $10.28 and a 1 year high of $26.92. The firm’s 50-day simple moving average is $16.09 and its 200 day simple moving average is $14.79. The firm has a market cap of $1.10 billion and a price-to-earnings ratio of -68.81.
Hedge Funds Weigh In On Omada Health
Institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP acquired a new stake in Omada Health in the fourth quarter valued at approximately $29,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Omada Health in the 4th quarter valued at $32,000. Raymond James Financial Inc. purchased a new stake in shares of Omada Health during the 2nd quarter worth $32,000. Inlight Wealth Management LLC acquired a new position in shares of Omada Health during the fourth quarter worth $45,000. Finally, Strs Ohio increased its holdings in Omada Health by 151.0% in the fourth quarter. Strs Ohio now owns 4,267 shares of the company’s stock valued at $67,000 after buying an additional 2,567 shares during the last quarter.
Analyst Upgrades and Downgrades
OMDA has been the subject of a number of research analyst reports. Evercore restated an “outperform” rating and set a $20.00 target price on shares of Omada Health in a report on Friday, May 8th. JPMorgan Chase & Co. reduced their price target on shares of Omada Health from $32.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Canaccord Genuity Group set a $24.00 price objective on shares of Omada Health in a research note on Friday, May 8th. Barclays upped their target price on shares of Omada Health from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of Omada Health in a report on Friday, May 8th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.91.
Check Out Our Latest Research Report on OMDA
About Omada Health
Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.
In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.
Recommended Stories
- Five stocks we like better than Omada Health
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Omada Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omada Health and related companies with MarketBeat.com's FREE daily email newsletter.
